NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis $1.00 +0.03 (+3.09%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.99 -0.01 (-1.00%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About enVVeno Medical Stock (NASDAQ:NVNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enVVeno Medical alerts:Sign Up Key Stats Today's Range$0.95▼$1.1250-Day Range$0.97▼$5.2552-Week Range$0.90▼$5.70Volume5.00 million shsAverage Volume1.22 million shsMarket Capitalization$19.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More enVVeno Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreNVNO MarketRank™: enVVeno Medical scored higher than 13% of companies evaluated by MarketBeat, and ranked 884th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for enVVeno Medical.Read more about enVVeno Medical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for enVVeno Medical are expected to grow in the coming year, from ($1.32) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enVVeno Medical is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enVVeno Medical is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenVVeno Medical has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about enVVeno Medical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.86% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in enVVeno Medical has recently increased by 18.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldenVVeno Medical does not currently pay a dividend.Dividend GrowthenVVeno Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.86% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in enVVeno Medical has recently increased by 18.00%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment-0.54 News SentimentenVVeno Medical has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for enVVeno Medical this week, compared to 0 articles on an average week.Search Interest8 people have searched for NVNO on MarketBeat in the last 30 days. MarketBeat Follows4 people have added enVVeno Medical to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, enVVeno Medical insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.71% of the stock of enVVeno Medical is held by institutions.Read more about enVVeno Medical's insider trading history. Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NVNO Stock News HeadlinesenVVeno Medical (NASDAQ:NVNO) Cut to Hold at LADENBURG THALM/SH SH3 hours ago | americanbankingnews.comThis Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?August 22 at 8:18 PM | msn.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)EnVVeno Medical Gets Not-Approvable Letter from FDA for VenoValveAugust 21 at 9:25 AM | marketwatch.comenVVeno tanks after FDA rejects VenoValve approvalAugust 20, 2025 | msn.comenVVeno Medical Corporation: enVVeno Receives Not-Approvable Letter from the FDA for the VenoValveAugust 20, 2025 | finanznachrichten.deenVVeno Medical stock plummets after FDA rejects VenoValve approvalAugust 20, 2025 | au.investing.comenVVeno Medical shares collapse after FDA denies VenoValve approvalAugust 20, 2025 | msn.comSee More Headlines NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed this year? enVVeno Medical's stock was trading at $3.02 on January 1st, 2025. Since then, NVNO shares have decreased by 66.9% and is now trading at $1.00. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) released its earnings results on Thursday, July, 31st. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. Who are enVVeno Medical's major shareholders? Top institutional shareholders of enVVeno Medical include Perceptive Advisors LLC (6.68%), Westside Investment Management Inc. (1.59%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.25%) and Universal Beteiligungs und Servicegesellschaft mbH (1.04%). Insiders that own company stock include Matthew Jenusaitis, Robert Gray, Sanjay Shrivastava and Hamed Alavi. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of enVVeno Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that enVVeno Medical investors own include Bionano Genomics (BNGO), VBI Vaccines (VBIV), Avino Silver & Gold Mines (ASM), Amarin (AMRN), Coherus Oncology (CHRS), Exelixis (EXEL) and Fortress Biotech (FBIO). Company Calendar Last Earnings7/31/2025Today8/23/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVNO CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.35% Return on Assets-53.49% Debt Debt-to-Equity RatioN/A Current Ratio11.81 Quick Ratio11.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book0.58Miscellaneous Outstanding Shares19,250,000Free Float16,167,000Market Cap$19.25 million OptionableOptionable Beta1.01 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NVNO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share enVVeno Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.